Market closedNon-fractional
Intellia Therapeutics/NTLA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Intellia Therapeutics
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Ticker
NTLA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Cambridge, United States
Employees
526
Website
www.intelliatx.com
NTLA Metrics
BasicAdvanced
$2.5B
Market cap
-
P/E ratio
-$5.35
EPS
1.83
Beta
-
Dividend rate
Price and volume
Market cap
$2.5B
Beta
1.83
Financial strength
Current ratio
9.029
Quick ratio
8.454
Long term debt to equity
8.889
Total debt to equity
10.7
Management effectiveness
Return on assets (TTM)
-24.15%
Return on equity (TTM)
-43.60%
Valuation
Price to revenue (TTM)
45.555
Price to book
2.47
Price to tangible book (TTM)
2.47
Price to free cash flow (TTM)
-5.732
Growth
Revenue change (TTM)
-1.63%
Earnings per share change (TTM)
-0.23%
3-year revenue growth (CAGR)
0.69%
3-year earnings per share growth (CAGR)
29.40%
What the Analysts think about NTLA
Analyst Ratings
Majority rating from 28 analysts.
NTLA Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$29M
-20.17%
Net income
-$107M
-77.68%
Profit margin
-371.62%
-72.04%
NTLA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.40
-$1.38
-$1.46
-$1.12
-
Expected
-$1.32
-$1.50
-$1.45
-$1.38
-$1.23
Surprise
5.99%
-7.93%
0.75%
-18.81%
-
NTLA News
AllArticlesVideos
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 days ago
BlueAllele Corporation Files Lawsuit for Patent Infringement against Intellia Therapeutics, Inc., for the Unauthorized Use of BlueAllele's Patented Bi-directional Insertion Templates
Business Wire·3 weeks ago
Kuehn Law Encourages Investors of Intellia Therapeutics, Inc. to Contact Law Firm
PRNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Intellia Therapeutics stock?
Intellia Therapeutics (NTLA) has a market cap of $2.5B as of July 26, 2024.
What is the P/E ratio for Intellia Therapeutics stock?
The price to earnings (P/E) ratio for Intellia Therapeutics (NTLA) stock is 0 as of July 26, 2024.
Does Intellia Therapeutics stock pay dividends?
No, Intellia Therapeutics (NTLA) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next Intellia Therapeutics dividend payment date?
Intellia Therapeutics (NTLA) stock does not pay dividends to its shareholders.
What is the beta indicator for Intellia Therapeutics?
Intellia Therapeutics (NTLA) has a beta rating of 1.83. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Intellia Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.